Press release

Innovative plant-based bioproduction company, Samabriva, announces the appointment of Pascal LIZIN, as its new chairman of the Board of Directors.

Amiens (France), June 21. 2023 — Samabriva, a biotechnology company specializing in bioproduction of high value molecules, such as natural active molecules (secondary metabolites) and recombinant proteins, for pharmaceuticals and the cosmetics market, is delighted to announce that Pascal Lizin has been appointed to the Board of Directors as Chairman.

Pascal has more than 30 years of Biopharmaceuticals company management experience at a senior level, including strategy development and execution. He has held also positions as board member in different sectors, including Chairman of the Board SFPIM, the Belgian Federal Holding and Investment Company, and as Head of Governmental and Public Affairs at the headquarters of GlaxoSmithKline Vaccines. Pascal will act as the interface between the company and the stakeholders creating a sustainable and positive environment for the international development of this innovative company.

Marina Guillet, CEO of Samabriva commented: *"Pascal is the ideal Chairman for Samabriva at this stage of the company's development to support its transition from a Research & Development company to an international CDMO. His extensive experience and network in academics, business and economics will help Samabriva support the company's international growth, develop its strategic partnerships and create both value for the company and the society."*

Commenting on his appointment, Pascal Lizin said *"I am very honoured to be joining the Samabriva team. I believe Samabriva has a transformative technology that will change the bioproduction environment offering new opportunities for the life sciences domain. The business model and the talented management team reinforce my opinion that Samabriva is capitalizing on the rapidly changing bioproduction environment through its innovation and will offer to pharmaceuticals and biotechnology companies a new vision for the future with predictability, competitive costs and high quality."*

About Samabriva: Samabriva is a plant-based biotechnology company that has successfully developed a proprietary bioproduction platform available to companies looking for affordable production of high-value molecules using large scale bioreactors.

The platform combines the advantages of plant-based systems (low cost, safe, serum- and animal-free) with traditional bioproduction in large-scale bioreactors to offer continuous, reliable and environmentally sustainable manufacture of a wide range of high value molecules all year round, in any location.

The manufacture of secondary metabolites currently lacks local scalable and sustainable production processes. Currently, secondary metabolites are mainly produced by growing plants in fields. However, extracting these compounds produces very small amounts from each plant. For example, 1 gram of vinblastine for chemotherapy treatment requires half a ton of dry leaves from the Madagascar periwinkle, *Catharanthus roseus* making the process costly and environmentally unsustainable.

The manufacture of recombinant proteins currently lacks cost effective and contaminant free production processes. Recombinant proteins are typically produced in bacterial (Escherichia coli) or more commonly in mammalian (typically Chinese Hamster Ovary (CHO)) cell cultures. These bioproduction systems are complex and costly. Mammalian cell cultures often use animal-derived media that require extensive purification of the final product to avoid any risk of virus or prion transmission.

The increasing demand for these high value molecules* is driving the need to produce them at scale in a more controlled and environmentally sustainable way.

Samabriva's innovative plant-based bioprocess platform uses *in vitro* hairy root culture to produce secondary metabolites and recombinant proteins at scale and with high yields.

Visit our website: www.samabriva.com

For further information please contact:

Marina Guillet, CEO, Samabriva - +33 (0) 322 092 830
Marina.guillet@samabriva.com

Notes:
*The global botanical and plant-derivative drug market is growing rapidly (at an estimated CAGR of 8.58% between 2018 and 2026[1]) while the recombinant protein market is expected to grow even faster (at a CAGR of 11.2% between 2021-2026[2]).

1. Global botanical and plant derivative drug market forecast 2018-2026 ; Marker Research Report
2. Https://www.mordorintelligence.com/industry-reports/recombinant-proteinmarket#:~:text=market%20overview,forecast%20period%2c%202021%2d2026. Recombinant protein market - growth, trends,covid-19 impact, and forecasts (2022 - 2027)- Mordor intelligence